Table 1.
Efficacy of platinum-based chemotherapy of BMF-NSCLC patients in phase II trials
| Authors, publication date, reference no. | Chemotherapy | Number of patients | Overall response rate (%) | Median overall survival (months) |
|---|---|---|---|---|
| Cotto et al. 1996 [15] | cisplatin + fotemustine | 31 | 23 | 4 |
| Minotti et al. 1998 [16] | cisplatin + teniposide | 23 | 35 | 5 |
| Franciosi et al. 1999 [17] | cisplatin + etoposide | 43 | 30 | 8 |
| Bernardo et al. 2002 [18] | carboplatin, navelbine, gemcitabine | 22 | 45 | 8 |
| Cortes et al. 2003 [19] | cisplatin + taxol | 26 | 38 | 5 |
| Barlesi et al. 2011 [20] | cisplatin + pemetrexed | 43 | 42 | 7 |